EUVIMEDEUVIMED entdecken
Crossref

Escitalopram moderately outperforms citalopram towards anti-neuroinflammation and neuroprotection in 6-hydroxydopamine-induced mouse model of Parkinson’s disease

Begench Ovlyakulov, Bei-Lei Hu, Hong-Yang Kan, Qing Guo, Xiao-Fen Li, Hui-Hui Fan, Hong-Mei Wu, Jian-Yong Wang, Xiong Zhang, Jian-Hong Zhu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Begench Ovlyakulov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine and Institute of Nutrition and Diseases, School of Public Health, Wenzhou Medical University, Wenzhou, Zhejiang, Ch…. Hauptthemen laut MEDLINE: Citalopram, Oxidopamine, Neuroprotective Agents, Disease Models, Animal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Citalopram and escitalopram are structurally close-related antidepressants and both forms are widely used in the world. We aimed to comparatively evaluate the anti-neuroinflammatory and neuroprotective effects of escitalopram and citalopram in Parkinson's disease (PD) mouse model. Mice were randomly divided into six groups and received 6-hydroxydopamine (6-OHDA) or vehicle administration. The mice were then treated with escitalopram, citalopram or saline for consecutive 7 days. Behaviors, neuroinflammation, neurotransmitters, and neurotoxicity were assessed. Results showed that citalopram but not escitalopram worsened body weight loss and increased freezing time in the PD mice. Both drugs had no impact on the anxiety-like behaviors but ameliorated the depressive-like behaviors as in elevated plus maze and sucrose splash tests. Escitalopram but not citalopram ameliorated motor discoordination in the PD mice as in rotarod test. In accordance, escitalopram but not citalopram attenuated the 6-OHDA-induced nigrostriatal dopaminergic loss. Further mechanistic investigations showed that both drugs mitigated activations of microglia and astrocytes and/or levels of pro-inflammatory cytokines in the PD mice, but escitalopram showed appreciably better effects in the substantia nigra. Neurotransmitter examination in the prefrontal cortex suggested that the two drugs had comparable effects on the disturbed neurotransmitters in the PD mice, but citalopram was prone to disrupt certain normal homeostasis. In conclusion, escitalopram is moderately superior than citalopram to suppress neuroinflammation and to protect against dopaminergic neuronal death and motor discoordination in the 6-OHDA-induced PD mice. Our findings imply that escitalopram shall be prescribed with priority over citalopram to treat PD patients with depression as escitalopram may meanwhile provide greater additional benefits to the patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CitalopramOxidopamineNeuroprotective AgentsDisease Models, AnimalEscitalopramAnimalsMaleMiceNeuroinflammatory DiseasesMice, Inbred C57BLCytokinesParkinson DiseaseHumansBehavior, AnimalDopaminergic NeuronsAnti-Inflammatory AgentsParkinsonian Disorders

Stichwörter der Autor:innen

CitalopramEscitalopramNeuroinflammationNeuroprotectionParkinson’s disease

Substanzen

CitalopramOxidopamineNeuroprotective AgentsEscitalopramCytokinesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Preventive Medicine and Institute of Nutrition and Diseases, School of Public Health, Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Neurology and Institute of Geriatric Neurology, the…
  • Department of Neurology and Institute of Geriatric Neurology, the Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Preventive Medicine and Institute of Nutrition and Diseases, School of Public Health, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Neurology and Institute of Geriatric Neurology, the Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: zhangxiong98@gmail.c…

Förderung

  • Zhejiang Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Ovlyakulov, B., Hu, B. L., Kan, H. Y., Guo, Q., Li, X. F., Fan, H. H., Wu, H. M., Wang, J. Y., Zhang, X., & Zhu, J. H. (2024). Escitalopram moderately outperforms citalopram towards anti-neuroinflammation and neuroprotection in 6-hydroxydopamine-induced mouse model of Parkinson’s disease. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112715

Vancouver

Ovlyakulov B, Hu BL, Kan HY, Guo Q, Li XF, Fan HH, et al. Escitalopram moderately outperforms citalopram towards anti-neuroinflammation and neuroprotection in 6-hydroxydopamine-induced mouse model of Parkinson’s disease. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112715

BibTeX
@article{Ovlyakulov2024,
  author = {Ovlyakulov, Begench and Hu, Bei-Lei and Kan, Hong-Yang and Guo, Qing and Li, Xiao-Fen and Fan, Hui-Hui and Wu, Hong-Mei and Wang, Jian-Yong and Zhang, Xiong and Zhu, Jian-Hong},
  title = {Escitalopram moderately outperforms citalopram towards anti-neuroinflammation and neuroprotection in 6-hydroxydopamine-induced mouse model of Parkinson’s disease},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112715}
}
Kostenlos starten →